英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

cato    音标拼音: [k'eto]
n. 男子名

男子名

Fortran-like CAI language for PLATO system on CDC 1604. "CSL
PLATO System Manual", L.A. Fillman, U Illinois, June 1966.


请选择你想看的字典辞典：
单词字典翻译
Cato查看　Cato　在百度字典中的解释百度英翻中〔查看〕
Cato查看　Cato　在Google字典中的解释Google英翻中〔查看〕
Cato查看　Cato　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Libtayo: Uses, Side Effects, Warnings - Drugs. com
    Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer Includes Libtayo side effects, interactions and indications
  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC . . .
    LIBTAYO is a prescription medicine used to treat adults with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC) and have previously received treatment with a hedgehog pathway inhibitor (HHI), or cannot receive treatment with a HHI
  • Libtayo more favorable than Keytruda for first-line . . .
    The FDA approved Libtayo in 2022 as a first-line treatment for advanced NSCLC, in combination with chemotherapy However, it has been unclear whether this new combination treatment could outperform Keytruda plus chemotherapy from a cost-effectiveness standpoint
  • Treatment in Advanced NSCLC | LIBTAYO® (cemiplimab-rwlc)
    Learn about LIBTAYO® (cemiplimab-rwlc) in the treatment of advanced non-small cell lung cancer (NSCLC) Review Important Safety Info Full Prescribing Information including Med Guide
  • Libtayo (cemiplimab) vs Krazati (adagrasib) - Everyone. org
    Libtayo (cemiplimab) vs Krazati (adagrasib) - Everyone org Everyone org
  • Cemiplimab: Side Effects, Uses, Dosage, Interactions, Warnings
    Cemiplimab is a cancer medicine that helps your immune system fight certain cancers What it treats Advanced or hard-to-treat: Some skin cancers (certain squamous cell and basal cell skin cancers) Some types of lung cancer (non–small cell lung cancer) Cemiplimab is available under the following different brand names: Libtayo, cemiplimab-rwlc
  • Regeneron immunotherapy combo comes up short in melanoma . . .
    The company has two cancer drugs approved, and one of them, the immunotherapy Libtayo, now generates more than $1 billion in annual sales The hope has been that fianlimab, a different kind of immunotherapy, might elevate that figure even higher as a complementary treatment that could amplify Libtayo’s effects
  • LIBTAYO® Full Prescribing Information | Regeneron
    1 3 Non-Small Cell Lung Cancer LIBTAYO in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is:
  • label - accessdata. fda. gov
    1 3 Non-Small Cell Lung Cancer LIBTAYO in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is:
  • Cemiplimab-rwlc - NCI - National Cancer Institute
    Cemiplimab-rwlc is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy) It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells It works by keeping cancer cells from suppressing the immune system This allows the immune system to attack and kill the cancer cells





中文字典-英文字典  2005-2009